Global Status Epilepticus Market to 2029 - Growth, Trends, Competitive Landscape, Patient and Forecast - ResearchAndMarkets.com

The "Global Status Epilepticus (SE)-Growth, Trends, Competitive Landscape, Patient and Market Forecast-2029" report has been added to ResearchAndMarkets.com's offering.

This report titled offers strategic insights into the global SE market along with the market size and estimates for the duration 2018 to 2029.

Status epilepticus is defined as persistent or recurrent seizures due to a failure of seizure termination mechanisms. In bilateral tonic-clonic seizures, it has been well accepted that 5 minutes of seizure activity constitutes status and has been shown that long-term consequences begin at 30 minutes of status. Similar data are lacking for focal status epilepticus. However, recently, the International League Against Epilepsy (ILAE) has proposed 10 minutes' duration as a time point for which focal status epilepticus can be defined and 60 minutes for which long-term consequences may occur in focal status. These are arbitrary terms which lack substantial evidence in the case of focal SE.

In 2015, SE was given a new definition as part of a revision of the classification of seizures. This is to help make diagnosing and managing seizures easier. Previous definitions didn't provide specific time points for when to treat SE or when long-term side effects or complications were likely to begin.

The seven major incidence of Status Epilepticus (SE) is expected to grow at a CAGR of around 0.58% during 2018-2029. United States accounts for the majority of the status epilepticus cases with 71,473 cases in 2018. Expected launch of potential therapy may increase the market size in the coming years, assisted by an increase in the incidence population & awareness of the disease

Market Drivers

• Awareness and Recognition
• Potential Pipeline Product
• Emphasizing on International collaborative research

Market Challenges

• Selecting the appropriate AEDs
• Uncertain clinical significance of Anesthetics
• Well timed Diagnosis

Key Topics Covered:

1.Table of Contents

2. Preface

3. Executive Summary

3.1. Epidemiology Snapshot

3.1.1. Status Epilepticus (SE) Patient Population in 2018

3.1.2. Status Epilepticus (SE) Patient Population in 2029

3.2. Market Snapshot

3.2.1. Status Epilepticus (SE) Market Size in 2018

3.2.2. Status Epilepticus (SE) Market Size in 2029

4. Market Trends

4.1. Market Dynamics

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

5. Key Insights

5.1. Epidemiology of Status Epilepticus (SE) in the Seven Major Markets, 2018

5.2. Potential Therapies Expected Launch

5.3. Market Definition & Methodology

6. Refractory Status Epilepticus (RSE)

6.1. Status Epilepticus (SE) Definition

6.2. Signs and Symptoms -NORSE

6.3. Cause

6.4. Types of Status Epilepticus

6.5. Diagnosis

6.5.1. Electroencephalography

6.5.2. Imaging

6.5.3. Neuroimaging

6.6. Pathophysiology

6.7. Management

6.7.1. Initial Management of Status Epilepticus

7. Current Treatment

7.1. Treatment Guidelines

7.2. Treatment Algorithm

8. Off-label/Marketed drugs

8.1. Executive Summary

8.2. List of off-label/Marketed drugs

9. Current Unmet Need and Opportunities

10. Epidemiology and Segmentation

10.1. Key Findings/Summary

10.2. Status Epilepticus (SE) Definition

10.3. Epidemiology Forecast Methodology

10.4. Assumptions & Sources Used

10.5. Incidence of Status Epilepticus (SE) in the Seven Major Market

11. Epidemiology by Countries

11.1. North America

11.2. United States

11.3. Europe-5

11.4. Asia: Japan

12. Key Upcoming Therapies

12.1. Pipeline Analysis of Potential Upcoming therapies

12.2. Promising Drug Candidates in Pipeline

12.3. Expected Launch Date

13. Ganaxolone: Marinus Pharmaceuticals

13.1. Therapy Description

13.2. Licensing & Designation

13.3. Clinical Development

13.4. Key Opinions Highlighting the impressive results of Ganaxolone

13.5. Competitive Clinical Trials Metrics Analysis

14. MHOS/SHP615: Takeda/Shire

14.1. Therapy Description

14.2. Licensing & Designation

14.3. Clinical Development

14.4. Key Opinions Highlighting the impressive results of MHOS/SHP615

14.5. Competitive Clinical Trials Metrics Analysis

15. Seven Major Market Analysis, Insights and Forecast, 2018-2029

15.1. Market Snapshot

15.2. Market Definition

15.3. Market Forecast Methodology

15.4. Price and Dose Assumptions

15.5. Assumptions & Sources Used

15.6. Market Analysis and Forecast by-

15.6.1. Class

15.6.2. Therapies

15.6.3. Route of Administration

15.7. Overview of Total Status Epilepticus (SE) Market

15.8. Market Size of Status Epilepticus (SE) in the Seven Major Market (2018-2029)

16. Seven Major Market: Country-Wise Market Analysis

17. North America

18. 5-Europe

18.1. United Kingdom

18.2. Germany

18.3. Italy

18.4. France

18.5. Spain

19. Asia: Japan

20. Comparative Efficacy and Safety Heat Map for Pipeline Products

21. What do physicians think?

21.1. Key Opinion Leader Views

22. Key Events Expected to Occur

23. Conclusion

23.1. Market Size in 2018 and 2029

23.2. Leading Companies

23.3. Leading Regional Markets

23.4. Market Forecast 2019-2019

23.5. The Future

24. Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/ykl9tw

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005365/en/